Pilar Maria Samper Ots

Dr. Pilar Maria Samper Ots

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NDNURIA RODRIGUEZ DE DIOS
NURIA RODRIGUEZ DE DIOS
FCFelipe Couñago
Felipe Couñago
MMMauricio Murcia-Mejia
Mauricio Murcia-Mejia
MRMikel Rico-Oses
Mikel Rico-Oses
PCPatricia Calvo-Crespo
Patricia Calvo-Crespo
JLJosé-Luis Lopez-Guerra
José-Luis Lopez-Guerra
PURPOSE: Radiation dose received by the neural stem cells of the hippocampus during whole-brain radiotherapy has been associated with neurocognitive decline. The key concern using hippocampal avoidance-prophylactic cranial irradiation (HA-PCI) in patients with small-cell lung cancer (SCLC) is the incidence of brain metastasis within the hippocampal avoidance zone. METHODS: This phase III trial enrolled 150 patients with SCLC (71.3% with limited disease) to standard prophylactic cranial irradiation (PCI; 25 Gy in 10 fractions) or HA-PCI. The primary objective was the delayed free recall (DFR) on the Free and Cued Selective Reminding Test (FCSRT) at 3 months; a decrease of 3 points or greater from baseline was considered a decline. Secondary end points included other FCSRT scores, quality of life (QoL), evaluation of the incidence and location of brain metastases, and overall survival (OS). Data were recorded at baseline, and 3, 6, 12, and 24 months after PCI. RESULTS: Participants' baseline characteristics were well balanced between the two groups. The median follow-up time for living patients was 40.4 months. Decline on DFR from baseline to 3 months was lower in the HA-PCI arm (5.8%) compared with the PCI arm (23.5%; odds ratio, 5; 95% CI, 1.57 to 15.86; P = .003). Analysis of all FCSRT scores showed a decline on the total recall (TR; 8.7% v 20.6%) at 3 months; DFR (11.1% v 33.3%), TR (20.3% v 38.9%), and total free recall (14.8% v 31.5%) at 6 months, and TR (14.2% v 47.6%) at 24 months. The incidence of brain metastases, OS, and QoL were not significantly different. CONCLUSION: Sparing the hippocampus during PCI better preserves cognitive function in patients with SCLC. No differences were observed with regard to brain failure, OS, and QoL compared with standard PCI.


17 November 2018 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
POPilar Maria Samper Ots
Pilar Maria Samper Ots
ACA. Luis Cardo
A. Luis Cardo
COC. Vallejo Ocaña
C. Vallejo Ocaña
MRM. A. Cabeza Rodríguez
M. A. Cabeza Rodríguez
LEL. A. Glaria Enríquez
L. A. Glaria Enríquez
JVJ. Olivera Vegas
J. Olivera Vegas

2 September 2015 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ACAntonio Jose Conde-Moreno
Antonio Jose Conde-Moreno
JLJosé-Luis Lopez-Guerra
José-Luis Lopez-Guerra
VMV. A. Macias
V. A. Macias
MTM. L. Vázquez de la Torre
M. L. Vázquez de la Torre
POPilar Maria Samper Ots
Pilar Maria Samper Ots
JEJosé Expósito
José Expósito

18 March 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
SMSara Montemuiño
Sara Montemuiño
NDNURIA RODRIGUEZ DE DIOS
NURIA RODRIGUEZ DE DIOS
MMMargarita Martín
Margarita Martín
BTBegoña Taboada
Begoña Taboada
PCPatricia Calvo-Crespo
Patricia Calvo-Crespo
FCFelipe Counago
Felipe Counago
Background: The optimal induction treatment in potentially-resectable stage IIIA-N2 NSCLC remains undefined. Aim: To compare neoadjuvant high-dose chemoradiotherapy (CRT) to neoadjuvant chemotherapy (CHT) in patients with resectable, stage IIIA-N2 non-small-cell lung cancer (NSCLC). Methods: Retrospective, multicentre study of 99 patients diagnosed with stage cT1-T3N2M0 NSCLC who underwent neoadjuvant treatment (high-dose CRT or CHT) followed by surgery between January 2005 and December 2014. Results: 47 patients (47.5%) underwent CRT and 52 (52.5%) CHT, with a median follow-up of 41 months. Surgery consisted of lobectomy (87.2% and 82.7%, in the CRT and CHT groups, respectively) or pneumonectomy (12.8% vs. 17.3%). Nodal downstaging (to N1/N0) and Pathologic complete response (pCR; pT0pN0) rates were significantly higher in the CRT group (89.4% vs. 57.7% and 46.8% vs. 7.7%, respectively; p < 0.001)). Locoregional recurrence was significantly lower in the CRT group (8.5% vs. 13.5%; p = 0.047) but distant recurrence rates were similar in the two groups. Median PFS was 45 months (CHT) vs. “not reached” (CRT). Median OS was similar: 61 vs. 56 months (p = 0.803). No differences in grade ≥3 toxicity were observed. On the Cox regression analysis, advanced pT stage was associated with worse OS and PFS (p < 0.001) and persistent N2 disease (p = 0.002) was associated with worse PFS. Conclusions: Compared to neoadjuvant chemotherapy alone, a higher proportion of patients treated with preoperative CRT achieved nodal downstaging and pCR with better locoregional control. However, there were no differences in survival. More studies are needed to know the optimal treatment of these patients.

1 September 2015 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
POPilar Maria Samper Ots
Pilar Maria Samper Ots
JGJulia Luisa Muñoz García
Julia Luisa Muñoz García
YKYesika Ríos Kavadoy
Yesika Ríos Kavadoy
MPMa Luz Couselo Paniagua
Ma Luz Couselo Paniagua
EIElena Villafranca Iturre
Elena Villafranca Iturre
MGMa Magdalena Márquez García-Salazar
Ma Magdalena Márquez García-Salazar
To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen deprivation therapy (ADT). Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of the adult population. However, prevalence rates are much higher in PCa patients (pts) who undergo ADT. Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients were divided into 3 groups based on the duration of ADT (6, 12-18, ≥24 months) and compared to a control group without ADT. MetS was defined according to NCEP ATP III criteria. Osteoporosis was assessed by DEXA. A total of 270 pts, treated from November 2011 to October 2012, were included. Of these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was significantly higher (71.3 vs. 69.38 years, p = 0.028). MetS prevalence was 50% in the control group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after 12-18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA. Of those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis. The prevalence of MetS in pts with PCa treated with radical RT was higher (47%) than in the general population. However, there were no significant differences in the duration of ADT administration. The prevalence of osteoporosis was low. These findings suggest that the prevalence of MetS in PCa patients may be higher than previously reported.